Biote Corp. (BTMD)
BTMD trades on Nasdaq in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1819253/000119312526106099/0001193125-26-106099-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BTMD on Nasdaq |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001819253 |
| SEC industry code | Medicinal Chemicals & Botanical Products |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $192.2M |
| Net income | $27.0M |
| Operating income | $35.6M |
| Net margin | 14.1% |
| Operating margin | 18.5% |
| Revenue growth | -2.5% |
| Cash | $24.1M |
| Total assets | $107.6M |
| P/E (computed) | 1.3× |
| P/S (computed) | 0.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $8.9M cash; operating cash flow $3.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 35,877,468 (2026-11-04); 45,662,630 a year earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Dallas, Texas, United States | PCAOB Form AP 2026-03-23 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $202K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $43.3M | $407K | $3.7M | $8.9M | $124.2M | $178.9M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $44.2M | -$6.6M | -$1.2M | $11.2M | $125.0M | $183.5M | 10-Q 2026-08-07 |
| Q1 2026 2026-03-31 | $44.9M | $2.3M | $3.9M | $5.3M | $101.6M | $188.2M | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | $46.4M | $2.0M | $7.6M | $24.1M | $103.1M | $192.2M | 10-K 2026-03-13 |
| Q3 2025 2025-09-30 | $48.0M | $8.2M | $14.1M | $28.0M | $104.7M | $195.6M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $48.9M | $3.2M | $7.1M | $19.6M | $106.3M | $199.1M | 10-Q 2026-08-07 |
| Q1 2025 2025-03-31 | $49.0M | $13.7M | $6.5M | $41.7M | $107.8M | $199.4M | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | $49.8M | $3.7M | $12.4M | $39.3M | $109.4M | $197.2M | 10-K 2026-03-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2025-04-09 |
| Latest annual report | 10-K | 2026-03-13 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-02 |
Source: SEC EDGAR submissions feed, 413 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.5% |
| 1 month | +2.4% |
| 3 months | -28.5% |
| Year to date | -59.0% |
| 1 year | -59.0% |
| From 52-week high | -62.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| FTLF | FitLife Brands Inc. | $6.83 | -19.46% | $64.1M |
| ISPR | Ispire Technology Inc. | $1.52 | -10.06% | $87.8M |
| GLAS | Glass House Brands Inc. Subordinate Voting Shares | $1.29 | +1.57% | $113.5M |
| BON | Bon Natural Life Limited | $1.09 | -0.91% | $8.9M |
| NAGE | Niagen Bioscience Inc. | $2.01 | -2.66% | $159.2M |
| MTEX | Mannatech Incorporated | $3.76 | -40.32% | $7.3M |
| MDWD | MediWound Ltd. | $13.55 | +5.04% | $195.0M |
| NAII | Natural Alternatives International Inc. | $0.9700 | +0.35% | $6.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier